Unlike other tumor types in which B2M mutations have been associated with a lack of response to immune checkpoint inhibitors, among immunotherapy-naïve CRC patients, up to 85% of tumors with B2M mutations achieve clinical benefit with immunotherapy, most notably in MSI-H tumors [65]. This evidence concerns the gene B2M and neoplasm.